New biologic GB-0895 enters first human safety trial for asthma and COPD
NCT ID NCT07116889
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage study is testing an experimental drug called GB-0895 in 156 adults with mild-to-moderate asthma or COPD. The main goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo as an injection under the skin. This is a first-in-human trial, so there is no proof yet that GB-0895 improves breathing or disease control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GB-0895 (an experimental biologic drug given as an injection under the skin)
What this could lead to
If safe and effective, GB-0895 could become a new treatment option to help control asthma or COPD symptoms.
What could go wrong
This is a very early Phase 1 trial focused on safety, not on whether the drug works. It involves only 156 people, so results may not apply to everyone. Side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alcanza
DeLand, Florida, 32720, United States
-
Charite Research Organization GmbH
Berlin, Germany
-
DM Clinical Research
Tomball, Texas, 77375, United States
-
Fraunhofer Institut fur Toxikologie and Experimentelle Medizin (ITEM)
Hanover, Germany
-
Hammersmith Medicines Research
London, United Kingdom
-
IKF Pneumologie
Frankfurt, Germany
-
Medicines Evaluation Unit (MEU)
Manchester, United Kingdom
-
Miami Research Institute of South Florida
Miami, Florida, 33173, United States
-
Nucleus Network
Saint Paul, Minnesota, 55114, United States
-
Omega Research
Orlando, Florida, 32808, United States
-
Queen Anne Street Medical Center
London, United Kingdom
-
Simbec-Orion Clinical Development
Merthyr Tydfil, United Kingdom
-
Southeastern Research Center
Winston-Salem, North Carolina, 27103, United States